About Jasper
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic to deplete mast cells and treat chronic mast diseases such as chronic urticaria, asthma and. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU or with CIndU and is planning to initiate a clinical study in patients with asthma. To date, briquilimab has a demonstrated efficacy and safety profile in over 160 dosed subjects and healthy volunteers.